Steroid-sparing strategies for managing ICI-induced arthritis: safety and oncological outcomes.

Le résumé fourni par la source

OBJECTIVES: Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but often cause immune-related adverse events (irAEs), including ICI-induced arthritis. Managing these rheumatic irAEs (R-irAEs) frequently requires prolonged glucocorticoid (GC) use, potentially compromising cancer outcomes. This study evaluates the use of conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs) and biologic DMARDs (b-DMARDs) as steroid-sparing agents in ICI-induced arthritis, focusing on their safety and efficacy. METHODS: We retrospectively analysed patients with ICI-induced arthritis treated at our centre (January 2019-January 2024). Demographic, oncologic, and treatment data were collected. Patients were grouped into GC-only and GC+DMARD (cs- or bDMARDs) groups. The primary endpoint was the steroid-sparing effect of DMARDs, with secondary endpoints evaluating time to cancer progression. RESULTS: Among 31 patients (68% male, mean age 69.5 years), the most common cancers were non-small cell lung cancer (35%) and melanoma (19%). Arthritis presentations included arthralgias, mono/oligoarthritis, polyarthritis, and polymyalgia rheumatica-like syndrome. Eighteen patients were treated with cs- or b-DMARDs, of whom 61% within 2 months and 72% within 4 months from the onset of ICI-induced arthritis. DMARD-treated patients had significantly lower cumulative steroid use (p=0.047) with no adverse impact on time to cancer progression (p=0.27). IL-6 inhibitors showed particular promise in managing chronic arthritis without compromising oncologic outcomes. CONCLUSIONS: DMARDs offer a safe and effective steroid-sparing strategy for ICI-induced arthritis, preserving cancer treatment efficacy. Early DMARD initiation could benefit patients needing long-term management of R-irAEs. Prospective studies are needed to refine treatment protocols, balancing immune modulation with oncological outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.